Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Citation metadata

From: The New England Journal of Medicine(Vol. 381, Issue 24)
Publisher: Massachusetts Medical Society
Document Type: Report
Length: 53 words

Document controls

Main content

Abstract :

The allosteric inhibitor asciminib was active in 150 heavily pretreated patients with Philadelphia chromosome-positive chronic myeloid leukemia who had resistance to or unacceptable side effects from tyrosine kinase inhibitors. These patients include those whom ponatinib had failed and those with a T315I mutation. Low-grade reversible toxic effects occurred in a minority of patients.

Source Citation

Source Citation   

Gale Document Number: GALE|A616011373